Skip to main content

New Drug Approvals Archive for 2002

See also: New Indications and Dosage Forms for 2002

Faslodex (fulvestrant) Injection

Date of Approval: April 25, 2002
Company: AstraZeneca
Treatment for: Breast Cancer

Faslodex (fulvestrant) is an estrogen receptor antagonist indicated for the treatment of hormone receptor positive metastatic breast cancer.

Lexapro (escitalopram oxalate) Tablets and Oral Solution

Date of Approval: August 14, 2002
Company: Allergan, Inc.
Treatment for: Depression, Generalized Anxiety Disorder

Lexapro (escitalopram oxalate) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder and for the treatment of generalized anxiety disorder (GAD).

Pegasys (peginterferon alfa-2a) Injection

Date of Approval: October 16, 2002
Company: Hoffmann-La Roche
Treatment for: Hepatitis C

Pegasys (peginterferon alfa-2a) is a covalent conjugate of recombinant alfa-2a interferon indicated for the combination treatment of adults with chronic hepatitis C.

Humira (adalimumab) Injection

Date of Approval: December 31, 2002
Company: Abbvie, Inc.
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Active, Crohn's Disease, Maintenance, Psoriasis, Juvenile Idiopathic Arthritis, Ulcerative Colitis, Hidradenitis Suppurativa, Uveitis

Humira (adalimumab) is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF) indicated for the treatment of plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, juvenile idiopathic arthritis, ulcerative colitis, hidradenitis suppurativa, and certain types of uveitis.

New drug approvals archive

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.